Investment Risk Analysis: Interface Clinical Services Ltd (06076464)

1. Risk Rating: LOW

This is an 18-year-old, audited, medium-sized company with a consistent growth and profitability record, a strong balance sheet (net assets of £15.36M), no evident external borrowings, and the backing of a substantial corporate parent (IQVIA Ltd, >75% owner). Filings are current and the audit opinion is unqualified with no going concern uncertainties. The rating is tempered from "minimal" only by a notable cash decline in 2024 and a PSC register inconsistency, both discussed below.

2. Key Concerns

1. Cash position halved despite record profits. Cash fell from £6.95M (2023) to £3.12M (2024) — a £3.8M decline — in a year when pre-tax profit was £7.86M and no dividend was declared. Total assets simultaneously grew by ~£9.1M, implying substantial absorption into receivables, accrued/contract income, or intercompany balances. Non-cash assets now stand at roughly £20.9M against turnover of £26.3M, which is a high ratio. The composition and recoverability of these assets is the single most important unanswered question in this data set.

2. PSC register inconsistency. The register simultaneously lists IQVIA Ltd (>75% ownership) and Xxxxxx Xxxxxxxxname shown to subscribers (50–75% ownership). These positions are mutually exclusive, indicating that historic PSC entries were not formally ceased following what appears to be an acquisition by IQVIA. This is an administrative compliance lapse rather than a financial red flag, but it should be regularised and the ownership history confirmed.

3. Parent dependency and customer concentration. The strategic report explicitly cites "continued support from our parent company IQVIA Ltd," and revenue is derived from pharmaceutical and NHS clients. Reliance on a parent for commercial support, combined with exposure to NHS procurement and pharma sector spending, creates concentration risk that is not quantifiable from the data provided.

3. Positive Indicators

• Strong, sustained growth: Turnover has more than doubled in three years (£11.5M in 2021 to £26.3M in 2024), with 23% growth in the latest year.
• High profitability: Pre-tax profit of £7.86M in 2024 (~30% margin), up from £3.87M in 2023. The net asset movement (£9.47M → £15.36M) reconciles precisely with post-tax retained earnings, indicating internally consistent reporting.
• Balance sheet strength: Net assets have increased every year from £1.65M (2019) to £15.36M (2024). Liabilities of £8.8M appear operational in nature; no bank debt is evident.
• Governance and compliance: Full audited accounts under the medium-sized regime; unqualified audit opinion (Thomas Coombs Limited); going concern confirmed; accounts and confirmation statement filed on time; professional corporate secretary (Xxxxxxxname shown to subscribers); directors' indemnity provisions in place; no disqualification records present in the data.
• Credible parent: IQVIA Ltd is part of a major global life sciences group, which materially reduces counterparty and continuity risk.

4. Due Diligence Notes

• Obtain the full notes to the 2024 accounts (truncated in the provided extract): specifically the debtor note (trade debtors vs. accrued income vs. amounts owed by group undertakings), the creditor note, and the related-party transactions note. This is essential to explain the £3.8M cash decline.
• Confirm intra-group arrangements: any cash pooling, intercompany lending, management charges, or transfer pricing arrangements with IQVIA entities.
• PSC remediation: verify that Xxxxxx Xxxxxxxxname shown to subscribers's PSC entries have been formally ceased and confirm the terms/timing of the change of control, including whether any earn-out or deferred consideration obligations exist.
• Revenue quality: assess contract tenure, renewal risk, and concentration within the NHS/pharma client base; confirm whether revenue is recurring or project-based.
• Lease and fixed asset commitments: the accounts reference long leasehold assets — confirm associated lease liabilities and commitments.
• Verify no off-register issues: litigation searches and director background checks were not covered by the data provided.

Names of the people mentioned are shown to subscribers. See subscription